ArticleInternational urogynecology journal2026
Pelvic Floor Reconstruction Using Mesh Versus Campbell Uterosacral Ligament Suspension: 2-Year Clinical Outcome.
Article in International urogynecology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and hypothesisThe present study is aimed at comparing the clinical outcome and patient satisfaction between transvaginal modified pelvic floor reconstruction using the titanized polypropylene lightweight mesh (MPFR-mesh) and transvaginal Campbell uterosacral ligaments suspension (C-USLS) in women with apical and anterior prolapse.
methodsWe performed a single-center retrospective cohort study including women who underwent a vaginal hysterectomy with concomitant MPFR-mesh or C-USLS from January 2018 and December 2020 with a 2-year follow-up. The primary outcome was composite surgical successful rate (retreatment of prolapse, Ba or Bp beyond 1 cm above the hymen, the C point above total vaginal length/2, or prolapse symptoms), and the secondary outcome included Pelvic Organ Prolapse Quantification (POP-Q) data (Ba、Bp、C, and TVL), adverse events, and patient satisfaction.
resultsA total of 175 patients were determined according to our study's inclusion criteria: 78 patients underwent MPFR-mesh, whereas 97 patients had C-USLS. With regard to cystocele, in the MPFR-mesh group, 68 (87.2%) had stage III, 10 (12.8%) had stage IV, and in the C-USLS group, 76 (78.4%) had stage III, 1 (1.0%) had stage IV; a significant difference was noted (p < 0.05). No differences were observed among women who underwent MPFR-mesh vs C-USLS with regard to the composite surgical success rate (88.5% vs 85.6%; p = 0.573). Consistent with multivariate analysis, after controlling for age, preoperative points Ba and C, body mass index, vaginal deliveries, posterior colporrhaphy, and perineorrhaphy, there was no discernable difference in recurrence rates between the two procedures. In addition, it was interesting to find that there was a difference in TVL and point C between the two groups after surgery (p < 0.05), but that there was no statistically significant difference in the Ba and Bp points (p > 0.05). Patient satisfaction was equally high in the MPFR-mesh group as in the C-USLS group (94.9% vs 96.9%; p = 0.768). Adverse events in the MPFR-mesh group vs the C-USLS group included mesh exposure (3.8% vs 0%), and ureteral kinking (0% vs 2.1%).
conclusionsModified pelvic floor reconstruction with mesh and C-USLS both have high composite surgical successful rates and patient satisfaction throughout 2 years. The C-USLS group may have longer vaginal length than the MPFR-mesh group after surgery. For patients with POP-Q stage III anterior prolapse and concurrent apical prolapse who are worried about potential mesh complications, this C-USLS could be an alternative.
Indexed as
Identifiers
40965663What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.